Stem Cell Patent Decision Prompts Questions in Parliament
Questions have been asked of Prime Minister David Cameron concerning the British Government’s position in relation to Court of Justice of the EU (CJEU) decision in the Brüstle v Greenpeace case. It seems IPCopy’s earlier posting on this matter reflects the concerns of many with interests in the future of regenerative medicine that such EU-wide decisions are profoundly damaging, especially when they undermine the decision of a member state to fund such research with taxpayers’ money.
That’s not mine! – Action checklist for marks registered by third parties in China.
If your brand has been registered in China without your authorisation or before you have even considered trade mark protection there, it can be very difficult to win the rights back, particularly if your mark has no current presence in the Chinese market.
We have put together a check list of the action that you would need to consider if you are in this difficult position.
America Invents Act (AIA) – IP Summit Brussels
As noted in an earlier post, the unitary patent and unified patent court in Europe was a hot topic of conversation at the IP Summit in Brussels recently. However, the unitary patent package was not the only major law change discussed and on 7 December 2012 I attended an informative session on “Filing Scenarios Before and After March 16, 2013” in relation to the America Invents Act (AIA).
This session was chaired by Eric Raciti from Finnegan with Malcolm T Meeks (Infineon Technologies AG) and Prof. Herb Munsterman (IIT Chicago-Kent College of Law) on the panel. The session focused on changes to the scope of prior art under AIA and also covered changes to the US grace period and new post-grant procedures that will be available to challenge granted US patents.
Design Treaty Comes of Age
For many The Hague Agreement for the international protection of industrial designs is one of those backwaters of IP law, a bit of a niche interest like the UPOV treaty for protection of plant varieties. However, this modest sibling of the PCT and Madrid Protocol won a major endorsement on 18 December 2012 when President Obama signed it into US law as part of the Patent Law Treaties Implementation Act.
So what happens now to human ES Cell patents in Europe?
Now that the dust has settled after a decade of uncertainty IPcopy surveys the scene to try and determine what the state of play is on patenting of human pluripotent stem cells in Europe.
Unitary Patent Package – the national patent alternative
As noted in Emily Weal’s earlier post on the subject (see here) patent applicants will still have the option of opting out of the unitary patent package if desired and applying for direct national patents.
A note of caution was sounded in the earlier post highlighting that not all of the 25 European countries that are part of the unitary patent package permit national phase entry from a PCT application.
In this post we take a closer look at which countries you need to keep an eye on.
IPcopy 